Stock BTAX BIOSTAX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biostax Corp.

Equities

BTAX

US45252A3059

Market Closed - OTC Markets
Other stock markets
 07:00:09 11/06/2024 pm IST 		5-day change 1st Jan Change
0.035 USD -17.63% Intraday chart for Biostax Corp. 0.00% -52.05%
20/05 Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
16/04 Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
AQ
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
AQ
Biostax Corp. Appoints Craig Suro as a Director
CI
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors
CI
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
AQ
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
AQ
Immune Therapeutics, Inc. will Change its Name to Biostax Corp
CI
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
AQ
Immune Therapeutics, Inc. Announces CEO Changes
CI
Immune Therapeutics, Inc. Announces Management Changes
CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
AQ
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
AQ
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih
CI
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare
PR
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BTAX Stock
  4. News Biostax Corp.